“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.
In this video, Eric A. Klein, MD, discusses the key takeaways of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study” and also shares what research is coming for the test. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Hormone therapy plus current treatments improves survival in prostate cancer
March 23rd 2023Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512